Real-World PV: Drafting Adverse Event Narratives with Copilot in a Phase III Biotech

Real-World PV: Drafting Adverse Event Narratives with Copilot in a Phase III Biotech

1. Problem / Context

Phase III biotech pharmacovigilance teams live in the red zone: Individual Case Safety Reports (ICSRs) demand consistent adverse event narratives and accurate MedDRA coding under strict EMA/FDA timelines. Our mid-market sponsor—about 1,200 employees—runs Argus for safety case management with a lean team and periodic contractor support. Volume spikes around database locks and interim analyses make narrative drafting a bottleneck. Quality findings often trace back to inconsistent timelines, unclear causality statements, and weak traceability to source documents. Meanwhile, inspection readiness requires demonstrable provenance, audit trails, and standardized language across cases.

2. Key Definitions & Concepts

• ICSR: A regulatory-mandated report of an adverse event, combining structured fields (e.g., seriousness, suspect product, reporter type) and a narrative summarizing clinical course, actions taken, and outcomes.
• MedDRA: The controlled vocabulary used to code events and medical concepts consistently across cases.
• Argus: A commonly used safety database where ICSRs are created, updated, and submitted.
• Microsoft Copilot in Word: A generative assistant that drafts text based on prompts and structured inputs within Word—useful for creating first-draft narratives.
• Agentic AI: A governed system of AI agents that can ingest documents, reason over clinical timelines/causality, validate against systems like Argus and dictionaries like MedDRA, and orchestrate next steps (e.g., drafting in Word, routing for sign‑off) with full provenance.
• Provenance links: Traceable references from each narrative sentence back to source PDFs/emails, enabling auditability and inspector confidence.

3. Why This Matters for Mid-Market Regulated Firms

Mid-market biotechs face the same oversight as large pharmas without their headcount. Narrative backlogs slow time-to-submission; inconsistencies trigger rework and QA observations. Lean teams can’t afford brittle automations that break on every template change, nor black boxes that erode inspection trust. Agentic AI—paired with Microsoft Copilot and underpinned by solid governance—offers a pragmatic path: reduce narrative cycle time, improve consistency, and strengthen inspection readiness without expanding headcount. As a governed AI and agentic automation partner for the mid-market, Kriv AI focuses on outcomes that withstand regulator scrutiny and real-world volume spikes.

4. Practical Implementation Steps / Roadmap

1. Source ingestion: Agents ingest emails, site PDFs, and E2B attachments. They identify patient, event, suspect drug, dosage, start/stop dates, and seriousness.
2. Fact extraction and normalization: Extracted entities are normalized (e.g., dates to ISO, dosage units standardized). Events are mapped to preliminary MedDRA terms.
3. Clinical reasoning: Agents build a clinical timeline, reconcile inconsistencies (e.g., onset before first dose), and surface conflicts for human attention.
4. Validation against Argus and MedDRA: Extracted facts are cross-checked against current Argus fields and the MedDRA hierarchy; missing or conflicting data triggers exception handling.
5. Narrative drafting in Word via Copilot: With validated facts and curated prompts, Microsoft Copilot drafts a consistent narrative: patient background, chronology, actions taken, outcomes, and sponsor causality language.
6. Human-in-the-loop review: Safety physicians review within Word, with inline provenance links back to source snippets. Edits are captured and fed back to improve prompts and extraction rules.
7. Governed handoff to Argus: A validated adapter updates narrative and codes into Argus, with schema validation and reject/repair flows.
8. Audit trail and dashboards: Every step is logged—data lineage, validation results, draft versions, reviewer decisions—supporting inspection readiness.

5. Governance, Compliance & Risk Controls Needed

• Data minimization and access control: Limit PII exposure; apply role-based access so only authorized safety staff can view identifiable data.
• Provenance-by-design: Maintain sentence-level links to source evidence so inspectors can trace assertions back to documents.
• Model risk management: Catalog prompts, model versions, and evaluation results; validate that Copilot outputs align with approved narrative templates and causality language.
• Schema validation and adapters: Prevent “pilot‑graveyard” failures by avoiding brittle exports. A governed Argus adapter with strict schema checks and exception queues protects scale-out.
• Human oversight and SOP alignment: Narrative drafting is assistive, not autonomous; physician sign-off remains mandatory. All flows map to existing SOPs and work instructions.
• Regional guardrails: Apply different templates and logic for US vs EU cases, including signal-review guardrails before extending to new jurisdictions.

Kriv AI often acts as the governance wrapper—designing the controls, adapters, and auditability that let mid-market teams use Copilot confidently without adding compliance risk.

6. ROI & Metrics

This Phase III biotech realized:

• 45% reduction in narrative cycle time (from draft request to physician-approved version)
• 30% fewer QA findings related to narrative consistency and MedDRA coding
• Improved inspection readiness through complete provenance and change logs

How to measure:

• Cycle time: Start when a case is triaged for narrative; stop at finalized physician sign-off in Argus.
• First-pass yield: Share of narratives approved without rework.
• Coding accuracy: Concordance with MedDRA preferred terms after QA review.
• Throughput: Narratives per FTE per week during spikes.
• Payback: Compare time saved per narrative (e.g., 90 minutes saved) across monthly volume; include avoided contractor hours and reduced findings remediation.

A realistic example: For 300 narratives/month at 1.5 hours saved each, that’s 450 hours reclaimed. Even with conservative contractor rates and platform costs, payback occurs within a few months while raising quality.

7. Common Pitfalls & How to Avoid Them

• Treating this as RPA: Narratives require clinical reasoning. Use agents that reconcile timelines/causality, not click-bots.
• Brittle integrations: Direct file dumps to Argus break at scale. Use a governed adapter with schema validation and retry/repair flows.
• Weak MedDRA mapping: Automap to LLT/PT naïvely and you’ll inflate QA findings. Incorporate hierarchy checks and physician feedback loops.
• No provenance: Without sentence-level links, inspectors lose confidence. Bake in evidence links.
• One-size-fits-all prompts: US and EU narratives differ. Parameterize prompts by region and product risk profile.
• Skipping exception handling: Ambiguous dates or missing seriousness flags should route to queues, not create silent errors.

30/60/90-Day Start Plan

First 30 Days

• Discovery: Inventory ICSR sources (sites, partners, mailboxes), narrative templates, and Argus field usage.
• Data checks: Assess data quality for dates, doses, reporter types, and current MedDRA practice.
• Governance boundaries: Define human-in-the-loop checkpoints, approved causality language, and PII handling rules.
• Technical baseline: Stand up secure ingestion, MedDRA access, and a non-production Word + Copilot environment.

Days 31–60

• Pilot workflows: Automate ingestion, extraction, and validation against Argus sandbox; enable Copilot to draft in Word with provenance.
• Agentic orchestration: Add timeline/causality reasoning and exception queues.
• Security controls: Implement RBAC, audit logging, and prompt/version catalogs.
• Evaluation: Track cycle time, first-pass yield, and QA findings on a limited set (e.g., US cases only).

Days 61–90

• Scaling: Introduce the governed Argus adapter with schema validation; expand to higher-volume studies.
• Monitoring: Formalize dashboards for cycle time, exception rates, and coding concordance.
• Regional expansion: After proving signal-review guardrails, extend to EU cases and align templates.
• Stakeholder alignment: Update SOPs, train physicians and case processors, and set change control for prompts/templates.

9. Industry-Specific Considerations

• Phase III tempo: Expect spikes around DB locks and interim analyses; design elastic capacity and physician review bandwidth.
• E2B(R3) and Argus specifics: Validate structured fields before narrative drafting to avoid downstream submission issues.
• SUSAR sensitivity: Standardize sponsor causality language; ensure prompt templates capture key ICH E2A elements.
• Blinded studies: Guardrails to avoid inadvertent unblinding in narratives; restrict product names when necessary.
• Regional nuances: US vs EU narrative expectations differ; only expand regions after guardrails pass signal review and QA.

10. Conclusion / Next Steps

Agentic AI paired with Microsoft Copilot in Word provides a pragmatic path for mid‑market biotechs to draft adverse event narratives faster and more consistently—while improving inspection readiness. By validating extracted facts against Argus and MedDRA, preserving provenance, and keeping physicians firmly in the loop, teams avoid the pilot‑graveyard and deliver sustained operational gains. If you’re exploring governed Agentic AI for your mid-market organization, Kriv AI can serve as your operational and governance backbone.